MCL1 and hepatocellular carcinoma: From the results, HCC patients in the high PRDX1 expression group exhibited greater sensitivity to twelve drugs, including Sorafenib (multi-kinase inhibitor), Linsitinib (IGF-1R inhibitor), JAK inhibitor (AZ960), ERK inhibitor (ERK 2440), Mitochondrial inhibitor (Dihydrorotenone), IKK inhibitor (BMS-345541), IRAK4 inhibitor (IRAK4_4710), SYK inhibitor (Entospletinib), TGF-β Receptor I/II inhibitor (LY2109761), MCL-1 inhibitor (AZD5991), KRAS (G12C) inhibitor, and I−BET inhibitor (I-BET-762), than patients with low PRDX1 expression group.